U.S. Markets open in 3 hrs 36 mins

Prolor Biotech receives notice of allowance for new U.S. patent

Prolor Biotech announced that it received a notice of allowance from the U.S. Patent and Trademark Office for a new patent application covering the company's proprietary long-acting CTP-enhanced coagulation factors for the treatment of hemophilia: Factor VIIa-CTP, Factor Vll-CTP and Factor IX-CTP. The allowed claims cover both product composition and treatment methods. The new patent is expected to issue in the next few months.